Program
IL-2 Mutein/Fc Fusion Protein HM16390
Its studies are led by Hanmi Pharmaceutical.
Furthest: phase 1, since Nov 29, 20241 company-led study, 1 open or runningNext primary completion: Jul 2031 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hanmi Pharmaceutical | 11 open or running | phase 1since Nov 29, 2024 | Nov 29, 2024 | Jul 2031phase 1 · NCT06724016 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 29, 2024First study: phase 1 study in Advanced or Metastatic Solid TumorsFirst studyNCT06724016 · 292 planned · United States, South Korea
Ahead
- Jul 2031Primary completion: phase 1 study in Advanced or Metastatic Solid TumorsNCT06724016
TargetBeta
IL2 →read by rule
“A recombinant fusion protein and long-acting analog of the human cytokine interleukin 2 (IL-2; IL2) consisting of a variant form of IL-2, IL-2 mutein, ”NCIt, by rule
Other programs on IL2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| darleukinrule | Philogen | phase 3 | 9 |
| daromunrule | Philogen | phase 3 | 6 |
| Daxokafusp Alfa | Sanofi | phase 2 | 2 |
| SAR444336 | Sanofi | phase 2 | 2 |
| Anti-PD-1/IL-2 Fusion Protein TEV-56278 | Teva Pharmaceutical Industries | phase 1 | 2 |
| Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101rule | outpace-bio-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06724016Advanced or Metastatic Solid Tumors · United States, South Korea | 1 | Recruiting | Jul 2031 | 292 |
How it is read
Names in the registry
- “HM16390”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.